Innovation & intellectual property · 29/12/2008Updated: 10/17/2026 · 1 min read
Amgen Secures Interim Patent Extension for Mifamurtide
Summary
The United States Patent and Trademark Office has granted Amgen a second one-year interim extension of the term of its U.S. Patent No. 4,971,802, which covers the cancer treatment drug mifamurtide.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →